HR6434

The Freedom to Heal Act of 2025 creates a special registration under the Controlled Substances Act for Schedule I investigational drugs for use under the Federal Right to Try law. This means physicians can directly administer these drugs to eligible patients without full FDA approval, provided they meet specific requirements, including manufacturer agreement and guidance. This legislative change significantly streamlines the process for patients with life-threatening conditions to access experimental Schedule I treatments, bypassing some traditional regulatory hurdles. The money trail for this bill flows directly to pharmaceutical and biotechnology companies developing Schedule I investigational drugs. By facilitating physician access and administration, the bill expands the potential patient pool for these therapies, increasing demand and revenue for manufacturers. The mechanism is regulatory relief, allowing a new pathway for drug distribution and use outside of standard clinical trials. Companies with existing Schedule I investigational drugs in their pipelines are positioned to benefit from this expanded market access. Historically, the Right to Try Act of 2018 (signed into law in May 2018) aimed to provide similar access but faced challenges due to the Controlled Substances Act's restrictions on Schedule I substances. While specific market reactions to the 2018 act were muted for individual drug developers due to the Schedule I hurdle, this new bill directly addresses that barrier. For example, companies like $CMPS, which is developing psilocybin for depression, and $GHRS, focused on MDMA-assisted therapy, have historically faced significant regulatory hurdles. This bill removes a key one. The passage of the 2018 Right to Try Act did not immediately cause significant stock movements for specific companies, but this bill's direct targeting of Schedule I substances creates a more direct and measurable impact. Specific winners include companies developing Schedule I investigational drugs. $CMPS (Compass Pathways) stands to gain as its psilocybin therapy for treatment-resistant depression becomes more accessible. $GHRS (GH Research PLC), focused on 5-MeO-DMT for depression, will also benefit from expanded patient access. (Mind Medicine Inc.) and $ATAI (Atai Life Sciences N.V.), both with pipelines including various psychedelic compounds, will see increased market opportunities. There are no direct losers identified, as this bill expands access without restricting existing pathways. This bill has been referred to the Committee on Energy and Commerce and the Committee on the Judiciary. The next step is committee consideration, which involves hearings and potential amendments. Given the bipartisan sponsorship (Ms. Dean [D] and Mr. Crenshaw [R] are among the sponsors), the bill has a higher likelihood of advancing. If it passes committee, it will proceed to a floor vote in the House, then to the Senate for similar committee and floor votes. The timeline for passage is uncertain but could occur within the 119th Congress (2025-2026).